Drug-resistant tuberculosis threatens WHO's End-TB strategy

The Lancet Infectious Diseases

Volumn 17, Issue 7, 2017, Pages 674-675

  Mariandyshev, Andrei ^a   Eliseev, Platon ^a  

^a NORTHERN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INDIA; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PHILIPPINES; PRIORITY JOURNAL; RUSSIAN FEDERATION; SHORT COURSE THERAPY; SOUTH AFRICA; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 85019161795     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30246-3     Document Type: Note

References (13)

1. Sharma, A, Hill, A, Kurbatova, E, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis, 2017 published online May 9. http://dx.doi.org/10.1016/S1473-3099(17)30247-5.
2. WHO. On the road to ending TB: highlights from the 30 highest TB burden countries, 2016, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/204662/1/WHO_HTM_TB_2016.06_eng.pdf?ua=1.
3. WHO. Global tuberculosis report, 2016, 2016, World Health Organization, Geneva http://www.who.int/tb/publications/global_report/en/ (accessed April 22, 2017).
4. Roadmap to implement the tuberculosis action plan for the WHO European region 2016-2020, 2016, WHO http://www.euro.who.int/__data/assets/pdf_file/0020/318233/Roadmap-implement-TBC-action-plan-20162020.pdf?ua=1 (accessed April 22, 2017).
5. WHO. Tuberculosis surveillance and monitoring in Europe. http://www.euro.who.int/__data/assets/pdf_file/0020/334703/tuberculosis-surveillance-and-monitoring-in-europe-2017.pdf?ua=1, 2017.
6. The Global Fund. https://www.theglobalfund.org/ru/ (accessed April 22, 2017).
7. Cegielski, J Peter, Dalton, Tracy, Yagui, Martin, Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis. Clin Infect Dis 59:8 (2014 Oct 15), 1049–1063 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184341/ (accessed April 22, 2017).
8. Stop TB Partnership. Global drug-resistant TB initiative. http://www.stoptb.org/wg/mdrtb/default.asp (accessed April 22, 2017).
9. Global drug resistance TB initiatives. http://www.stoptb.org/wg/mdrtb/.
10. Global drug facility. http://www.stoptb.org/gdf/ (accessed April 22, 2017).
11. WHO. Treatment guidelines for drug-resistant tuberculosis (2016 update), 2016, World Health Organization http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/ (accessed April 22, 2017).
12. WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance, 2014, World Health Organization http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1 (accessed April 22, 2017).
13. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance, 2013, World Health Organization http://www.who.int/tb/publications/mdrtb-treatment-guideline/en/ (accessed April 22, 2017).